Sinopharm Group Management
Management criteria checks 4/4
Sinopharm Group's CEO is Yong Liu, appointed in Nov 2017, has a tenure of 6.42 years. total yearly compensation is CN¥6.28M, comprised of 33.1% salary and 66.9% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth HK$1.23M. The average tenure of the management team and the board of directors is 4.3 years and 5.3 years respectively.
Key information
Yong Liu
Chief executive officer
CN¥6.3m
Total compensation
| CEO salary percentage | 33.1% |
| CEO tenure | 6.4yrs |
| CEO ownership | 0.002% |
| Management average tenure | 4.3yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22
Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?
Jan 06What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?
Dec 25Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares
Dec 15We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Dec 04Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years
Nov 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | CN¥9b |
| Sep 30 2023 | n/a | n/a | CN¥9b |
| Jun 30 2023 | n/a | n/a | CN¥9b |
| Mar 31 2023 | n/a | n/a | CN¥9b |
| Dec 31 2022 | CN¥6m | CN¥2m | CN¥9b |
| Sep 30 2022 | n/a | n/a | CN¥8b |
| Jun 30 2022 | n/a | n/a | CN¥8b |
| Mar 31 2022 | n/a | n/a | CN¥8b |
| Dec 31 2021 | CN¥7m | CN¥2m | CN¥8b |
| Sep 30 2021 | n/a | n/a | CN¥8b |
| Jun 30 2021 | n/a | n/a | CN¥8b |
| Mar 31 2021 | n/a | n/a | CN¥8b |
| Dec 31 2020 | CN¥7m | CN¥2m | CN¥7b |
| Sep 30 2020 | n/a | n/a | CN¥7b |
| Jun 30 2020 | n/a | n/a | CN¥6b |
| Mar 31 2020 | n/a | n/a | CN¥6b |
| Dec 31 2019 | CN¥7m | CN¥2m | CN¥6b |
| Sep 30 2019 | n/a | n/a | CN¥6b |
| Jun 30 2019 | n/a | n/a | CN¥6b |
| Mar 31 2019 | n/a | n/a | CN¥6b |
| Dec 31 2018 | CN¥8m | CN¥2m | CN¥6b |
| Sep 30 2018 | n/a | n/a | CN¥6b |
| Jun 30 2018 | n/a | n/a | CN¥6b |
| Mar 31 2018 | n/a | n/a | CN¥5b |
| Dec 31 2017 | CN¥6m | CN¥1m | CN¥6b |
Compensation vs Market: Yong's total compensation ($USD866.18K) is about average for companies of similar size in the Hong Kong market ($USD923.19K).
Compensation vs Earnings: Yong's compensation has been consistent with company performance over the past year.
CEO
Yong Liu (54 yo)
6.4yrs
Tenure
CN¥6,276,000
Compensation
Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 5.3yrs | CN¥6.49m | 0.0032% CN¥ 2.1m | |
| President & Executive Director | 6.4yrs | CN¥6.28m | 0.0019% CN¥ 1.2m | |
| Chief Financial Officer | 3.1yrs | no data | no data | |
| Secretary to the Board | 5.3yrs | no data | no data |
4.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: 1099's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 5.3yrs | CN¥6.49m | 0.0032% CN¥ 2.1m | |
| President & Executive Director | 6.3yrs | CN¥6.28m | 0.0019% CN¥ 1.2m | |
| Non-Executive Vice Chairman | 13.9yrs | no data | no data | |
| Non-Executive Director | 2.8yrs | no data | no data | |
| Chief Supervisor | 2.8yrs | no data | no data | |
| Non-Executive Director | 16.7yrs | no data | no data | |
| Independent Non-Executive Director | 3.6yrs | CN¥350.00k | no data | |
| Independent Non-Executive Director | 3.6yrs | CN¥350.00k | no data | |
| Non-Executive Director | 6.6yrs | no data | no data | |
| Non-Executive Director | 5.3yrs | no data | no data | |
| Independent Non-Executive Director | 5.3yrs | CN¥350.00k | no data | |
| Independent Non-Executive Director | 3.6yrs | CN¥350.00k | no data |
5.3yrs
Average Tenure
56yo
Average Age
Experienced Board: 1099's board of directors are considered experienced (5.3 years average tenure).